Accord Tolterodine

Tolterodine tartrate

Symptomatic treatment of urge incontinence &/or increased urinary frequency & urgency as may occur in patients w/ overactive bladder syndrome.

2 mg bd. Patients w/ impaired liver function or severely impaired renal function (GFR <30 mL/min) 1 mg bd.

May be taken with or without food.

Hypersensitivity. Urinary retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe ulcerative colitis, toxic megacolon.

Significant bladder outlet obstruction at risk of urinary retention; GI obstructive disorder (eg, pyloric stenosis); autonomic neuropathy; hiatus hernia; risk for decreased GI motility. Congenital or documented acquired QT prolongation; electrolyte disturbances eg, hypokalemia, hypomagnesaemia, hypocalcaemia; bradycardia; relevant pre-existing cardiac diseases ie, cardiomyopathy, myocardial ischaemia, arrythmia, CHF; concomitant administration of drugs known to prolong QT-interval including Class IA & III anti-arrhythmics. Concomitant treatment w/ potent CYP3A4 inhibitors. Renal impairment; hepatic disease. May affect ability to drive & operate machine. Pregnancy & lactation. Not recommended for childn.

Headache; dry mouth. Bronchitis; dizziness, somnolence, paresthesia; dry eyes, abnormal vision including abnormal accommodation; vertigo; palpitations; dyspepsia, constipation, abdominal pain, flatulence, vomiting, diarrhoea; dry skin; dysuria, urinary retention; fatigue, chest pain, peripheral oedema; increased wt.

Increased serum conc w/ potent CYP3A4 inhibitors (eg, macrolide antibiotics, antifungal agents & antiproteases). More pronounced therapeutic effect & side effects w/ drugs that possess antimuscarinic properties. Reduced therapeutic effect w/ muscarinic cholinergic receptor agonist. Decreased effects of prokinetics (eg, metoclopramide & cisapride).

Drugs for Bladder & Prostate Disorders

G04BD07 - tolterodine ; Belongs to the class of urinary antispasmodics.

P₁S₁S₃